Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Exosomes as a tumor immune escape mechanism: possible therapeutic implications.

Ichim TE, Zhong Z, Kaushal S, Zheng X, Ren X, Hao X, Joyce JA, Hanley HH, Riordan NH, Koropatnick J, Bogin V, Minev BR, Min WP, Tullis RH.

J Transl Med. 2008 Jul 22;6:37. doi: 10.1186/1479-5876-6-37.

2.

Activated T cell exosomes promote tumor invasion via Fas signaling pathway.

Cai Z, Yang F, Yu L, Yu Z, Jiang L, Wang Q, Yang Y, Wang L, Cao X, Wang J.

J Immunol. 2012 Jun 15;188(12):5954-61. doi: 10.4049/jimmunol.1103466. Epub 2012 May 9.

3.

Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis.

Abusamra AJ, Zhong Z, Zheng X, Li M, Ichim TE, Chin JL, Min WP.

Blood Cells Mol Dis. 2005 Sep-Oct;35(2):169-73.

PMID:
16081306
4.

Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape.

Huber V, Fais S, Iero M, Lugini L, Canese P, Squarcina P, Zaccheddu A, Colone M, Arancia G, Gentile M, Seregni E, Valenti R, Ballabio G, Belli F, Leo E, Parmiani G, Rivoltini L.

Gastroenterology. 2005 Jun;128(7):1796-804.

PMID:
15940614
5.

Suppression of FasL expression in tumor cells and preventing TNF-induced apoptosis was better for immune cells survival.

Xu G, Zhang J.

J Cancer Res Clin Oncol. 2008 Oct;134(10):1043-9. doi: 10.1007/s00432-008-0393-3. Epub 2008 May 7.

PMID:
18461366
6.

Exosome removal as a therapeutic adjuvant in cancer.

Marleau AM, Chen CS, Joyce JA, Tullis RH.

J Transl Med. 2012 Jun 27;10:134. doi: 10.1186/1479-5876-10-134.

7.

Tumor counterattack: fact or fiction?

Igney FH, Krammer PH.

Cancer Immunol Immunother. 2005 Nov;54(11):1127-36. Epub 2005 May 12. Review.

PMID:
15889255
8.

Exosomes secreted by human placenta carry functional Fas ligand and TRAIL molecules and convey apoptosis in activated immune cells, suggesting exosome-mediated immune privilege of the fetus.

Stenqvist AC, Nagaeva O, Baranov V, Mincheva-Nilsson L.

J Immunol. 2013 Dec 1;191(11):5515-23. doi: 10.4049/jimmunol.1301885. Epub 2013 Nov 1.

10.

Strategies of tumor immune evasion.

Seliger B.

BioDrugs. 2005;19(6):347-54. Review.

PMID:
16392887
11.

Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo.

Yang D, Torres CM, Bardhan K, Zimmerman M, McGaha TL, Liu K.

J Immunol. 2012 May 1;188(9):4441-9. doi: 10.4049/jimmunol.1103035. Epub 2012 Mar 28.

12.

Improving cancer immunotherapy by targeting tumor-induced immune suppression.

Stewart TJ, Smyth MJ.

Cancer Metastasis Rev. 2011 Mar;30(1):125-40. doi: 10.1007/s10555-011-9280-5. Review.

PMID:
21249424
13.

Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs.

Whiteside TL, Mandapathil M, Szczepanski M, Szajnik M.

Bull Cancer. 2011 Feb;98(2):E25-31. doi: 10.1684/bdc.2010.1294. Review.

14.

[Immune evasion of human lung carcinoma cell A549 suppressed by human lymphoma cell Jurkat via Fas/FasL pathway].

Wang H, Zhang G, Dai J, Min J.

Zhongguo Fei Ai Za Zhi. 2010 Jul;13(7):681-5. doi: 10.3779/j.issn.1009-3419.2010.07.05. Chinese.

15.

Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?

Malmberg KJ.

Cancer Immunol Immunother. 2004 Oct;53(10):879-92. Epub 2004 Jul 28. Review.

PMID:
15338206
16.
18.

The immunogenicity of dendritic cell-derived exosomes.

Quah BJ, O'Neill HC.

Blood Cells Mol Dis. 2005 Sep-Oct;35(2):94-110.

PMID:
15975838
19.

The Fas/Fas ligand system and cancer: immune privilege and apoptosis.

Abrahams VM, Kamsteeg M, Mor G.

Mol Biotechnol. 2003 Sep;25(1):19-30. Review.

PMID:
13679631
20.

Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.

Bennett MW, O'connell J, O'sullivan GC, Roche D, Brady C, Kelly J, Collins JK, Shanahan F.

Gut. 1999 Feb;44(2):156-62.

Supplemental Content

Support Center